News & Events

Learn about what's new with CMC Biologics

CMC Biologics and Genexine Announce Manufacturing Agreement for Genexine's Human Growth Hormone Drug, GX-H9

News

----_Genexine_Logo.jpgBOTHELL, Washington, U.S.A., and SEONGNAM, Republic of Korea, February 21, 2017 - CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Genexine, Inc. (KOSDAQ: 095700), an innovative biotechnology company focused on immuno-oncology, metabolic and orphan diseases, today announced that they have entered into a manufacturing agreement for the process transfer and cGMP manufacturing of Genexine’s GX-H9.

View or Download as a PDF  

CMC Biologics Enters into Manufacturing Agreement with CytoDyn

News

Agreement covers process development and manufacture of CytoDyn’s PRO 140

 


Bothell, WA, Copenhagen, Denmark, Berkeley, CA, and Tokyo, Japan– February 15, 2017
 –CMC Biologics, a
 global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, and CytoDyn Inc., a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection, announced today they have entered into an agreement for the process development and commercial manufacture of CytoDyn’s PRO 140.

View or Download as a PDF  

Follow Us
Join us on LinkedIn Follow us on Twitter